Approval · Notice of Compliance 27907 · 2022
MINT-RANITIDINE: Notice of Compliance 27907
Issued April 4, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27907
- Date
- April 4, 2022
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- APO-RANITIDINE (Apotex Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-RANITIDINE | 02526379 | Marketed |
| MINT-RANITIDINE | 02526387 | Marketed |
Medicinal ingredients
- RANITIDINE 150 MG per TAB
- RANITIDINE 300 MG per TAB